Frontlight ResearchEarly access
CompletedPhase 2
Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder
Key facts
- Who runs it
- Anders Fink-Jensen, MD, DMSci
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 60 people enrolled
- Started
- 1 Sept 2023
- Ended
- 22 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Psilocybin
- Maltodextrin
- Record updated
- 24 March 2026
Who can take part
- Age
- 20 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Bodyweight of 50-110 kg
- AUD according to DSM-5 criteria and alcohol dependence according to ICD-10
- AUD Identification Test (AUDIT) ≥ 15
- ≥ 5 heavy drinking days in the past 28 days prior to inclusion
Who cannot take part
- Current or previously diagnosed with any psychotic disorder or bipolar affective disorder
- Treatment with disulfiram, naltrexone, acamprosate and nalmefene within 28 days of inclusion
- Treatment with any serotonergic medication or drugs within one month prior inclusion
- Immediate family member with a diagnosed psychotic disorder
- History of delirium tremens or alcohol withdrawal seizures
- History of suicide attempt or present suicidal ideation at screening
- Present or former severe neurological disease including trauma with loss of consciousness > 30 min
- Cardiovascular disease defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, myocardial infarction within the last 12 months or uncontrolled hypertension (systolic blood pressure >165 mmHg, diastolic blood pressure >95 mmHg)
- Any oOther active substance use disorders (except nicotine) defined as a Drug Use Disorder Identification Test score >six/two (men/women) and investigator's clinical evaluation
- Any other condition that the clinician estimates can interfere with trial participation
- Impaired hepatic function (alanine transaminase >210/135 units/l men/women)
- Present or former abnormal QTc (>450/470 ms men/women)
- Withdrawal symptoms at screening (>nine on the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) (43)
- Women who are pregnant, breastfeeding, or intend to become pregnant or are not using adequate contraceptive measures considered highly effective (44)
- Unable to speak or understand Danish
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Note: The trial is only eligible for citizens of Denmark.
Read full original descriptionShow less
The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).
The 2 groups in the trial
- Psilocybin-assisted therapyTreatment being tested
45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.
Treatment: Psilocybin
- Placebo-assisted therapyPlacebo, for comparison
45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.
Treatment: Maltodextrin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.
- Publications
- Record updated
- 24 March 2026